Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

UNIFIED Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies

Coordinator
Erasmus Universiteit Rotterdam, Netherlands
Runs
1 November 2025 to 31 October 2030
Status
Running
EU funding
€12.6m
Total cost
€23.0m
Partners
51 organisations in 17 countries
Type
Research and Innovation Action
Grant agreement
101218845

What the project is doing

In the project's own words, from its summary on CORDIS.

Motivation: Failing to incorporate patient perspectives in healthcare decisions leads to sub-optimal care. Despite increasing emphasis from industry and policy-makers this is not yet common practice. Main objectives: UNIFIED is a public-private partnership involving universities, industry, patient groups, medical centres, HTA bodies, and clinical guideline organisations. It is designed to generate a UNIFIED Framework for obtaining a robust view of a health intervention’s full benefits to patients via (i) integrating three key data types: patient preference information, clinical outcome assessments, and digital health technology (DHT)-derived measures, and (ii) determining what patients consider minimum clinically important difference.

Leveraging cutting-edge AI, particularly Foundation Models, UNIFIED integrates these diverse patient-centred data types reliably, while employing advanced safeguards. UNIFIED uses a structured, interactive, and multimethod approach, fostering synergy between academic expertise and fast experience in pharmaceutical and MedTech industry. Validation of the initial framework will occur through well-aligned complementary use cases in five medical domains across Europe and Canada and an adoption approach for patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies.

Main deliverables: A robust evidence- and consensus-based UNIFIED Framework with recommendations for integrating patient-centred clinical-study endpoints. The framework will provide clear, actionable guidance for timely and effective use of patient-centred, DHT-derived data as clinical endpoints. Expected long-term impact: Through its evidence- and consensus-based framework and recommendations, UNIFIED empowers patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies to make patient-centred healthcare decisions.

This will drive measurable improvements across the healthcare ecosystem, benefitting patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies, and society. Ultimately, UNIFIED will enhance patient-centred care by ensuring healthcare decisions reflect true value to patients, thus improving patient outcomes, while ensuring healthcare’s long-term effectiveness and economic sustainability.

Who is involved

OrganisationCityCountryRole
Erasmus Universiteit RotterdamRotterdamNetherlandsCoordinator
European Academy of NeurologyWienAustriaParticipant
Medizinische Universitaet WienWienAustriaParticipant
AmgenDiegemBelgiumParticipant
Association Europeenne Pour La Maladie De ParkinsonBruxelles / BrusselBelgiumParticipant
Forum Des Patients EuropeensBruxelles / BrusselBelgiumParticipant
Iqvia Solutions BelgiumZaventemBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Ucb BiopharmaBruxelles / BrusselBelgiumParticipant
9197-1168 Quebec inMontrealCanadaParticipant
Cassie and Friends: A Society for Children with Juvenile Arthritis and other Rheumatic DiseasesVancouverCanadaParticipant
The Hospital for Sick ChildrenTorontoCanadaParticipant
University of CalgaryCalgary AlbertaCanadaParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Collaborate Project Management GmbHMunchenGermanyParticipant
Hochschule NeubrandenburgNeubrandenburgGermanyParticipant
Pfizer Pharma GmbHBerlinGermanyAssociatedpartner
Siemens Healthineers AGForchheimGermanyParticipant
H2o Pan European ObservatoryNordhavnDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Fundacion Publica Andaluza Progreso Y Salud M.p.SevillaSpainParticipant
Hus-YhtymaHelsinkiFinlandParticipant
Pfizer International OperationsParisFranceAssociatedpartner
The European Coalition for People Living with Obesity Company Limited by GuaranteeDublinIrelandParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyParticipant
Universita Degli Studi Di MilanoMilanoItalyParticipant
Childhood Cancer InternationalAmsterdamNetherlandsParticipant
Janssen Biologics BVLeidenNetherlandsParticipant
PancareBussumNetherlandsParticipant
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit TwenteEnschedeNetherlandsParticipant
Universiteit Van AmsterdamAmsterdamNetherlandsParticipant
Uniwersytet JagiellonskiKrakowPolandParticipant
Promptly - Software Solutions for Health Measures SATrofaPortugalParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Evinova ABMölndalSwedenAssociatedpartner
Molnlycke Health Care ABGoteborgSwedenParticipant
Iqvia LtdReadingUnited KingdomAssociatedpartner
Janssen Cilag LimitedHigh WycombeUnited KingdomAssociatedpartner
Pfizer LimitedSandwichUnited KingdomAssociatedpartner
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
Abbvie IncNorth Chicago IlUnited StatesParticipant
Amgen IncNewbury ParkUnited StatesAssociatedpartner
AstraZeneca Pharmaceuticals LPWilmingtonUnited StatesAssociatedpartner
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner
John Snow Labs Inc.LewesUnited StatesParticipant
Pfizer IncNew York CityUnited StatesParticipant
Varian Medical Systems Inc.Palo AltoUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI